Assessment of DW-MRI Measures : Reproducibility and Repeatability in Pelvic Imaging on MR-Linac With Healthy Volunteers
Launched by JULES BORDET INSTITUTE · Jun 12, 2024
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a type of MRI called functional MRI to see how reliable it is for measuring conditions in the pelvic area, like rectal and pelvic cancers. The researchers want to find out if they get consistent results when healthy volunteers undergo the MRI multiple times or when different observers look at the results. This information will help improve how we use functional MRI in the future for patients with pelvic diseases.
To be part of this study, participants need to be at least 18 years old and in good health. They should also be able to safely undergo an MRI scan. Unfortunately, people who have had previous radiation treatment to the pelvic area or have certain pelvic health issues cannot join. While the study is still in the planning stages and not yet recruiting participants, those who take part can expect to help researchers learn more about how reliable these MRI measurements are, which could ultimately benefit patients with pelvic cancers.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • ≥ 18 yo
- • Healthy
- • Volunteer
- • Ability to undergo an MRI
- Exclusion Criteria:
- • \< 18yo
- • Contraindication to undergoing an MRI (see safety questionnaire)
- • Previous pelvic irradiation
- • Pelvic pathology
About Jules Bordet Institute
The Jules Bordet Institute is a prestigious cancer research and treatment center located in Brussels, Belgium, dedicated to advancing oncology through innovative clinical trials and multidisciplinary care. As a leading sponsor of clinical research, the institute focuses on developing novel therapeutic approaches and improving patient outcomes in various cancer types. With a commitment to scientific excellence and collaboration, the Jules Bordet Institute leverages cutting-edge technologies and a robust network of healthcare professionals to foster breakthroughs in cancer treatment and enhance the quality of life for patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Madeline A Michel, MD
Principal Investigator
Jules Bordet Institute
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported